Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

被引:106
|
作者
Preaud, Emmanuelle [1 ]
Durand, Laure [2 ]
Macabeo, Berengere [2 ]
Farkas, Norbert [3 ]
Sloesen, Brigitte [4 ]
Palache, Abraham [5 ]
Shupo, Francis [6 ]
Samson, Sandrine I. [1 ]
机构
[1] Sanofi Pasteur MSD, F-69367 Lyon, France
[2] Sanofi Pasteur, F-69007 Lyon, France
[3] Novartis Vaccines & Diagnost AG, CH-4056 Basel, Switzerland
[4] GlaxoSmithKline, Rixensart, Belgium
[5] Abbott, NL-1381 CP Weesp, Netherlands
[6] Creativ Ceut Ltd, London SE1 9QQ, England
关键词
Influenza; Public health policy; Vaccines and immunization; Modeling; Epidemiology; COST-EFFECTIVENESS; EXCESS MORTALITY; ENGLAND; BURDEN; NORWAY; IMPACT; UNION;
D O I
10.1186/1471-2458-14-813
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels. Methods: A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data. Results: Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza-related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional +(sic)190 to +(sic)226 million yearly, in vaccination target groups. Conclusions: Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Seasonal influenza in Spain: Clinical and economic burden and vaccination programmes
    Perez-Rubio, Alberto
    Platero, Leticia
    Eiros Bouza, Jose Maria
    MEDICINA CLINICA, 2019, 153 (01): : 16 - 27
  • [12] Estimating the full health and economic benefits of current and future influenza vaccines
    Waterlow, Naomi R.
    Procter, Simon R.
    Eggo, Rosalind M.
    Jit, Mark
    BMC MEDICINE, 2023, 21 (01)
  • [13] Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis
    Sandmann, Frank G.
    van Leeuwen, Edwin
    Bernard-Stoecklin, Sibylle
    Casado, Itziar
    Castilla, Jesus
    Domegan, Lisa
    Gherasim, Alin
    Hooiveld, Mariette
    Kislaya, Irina
    Larrauri, Amparo
    Levy-Bruhl, Daniel
    Machado, Ausenda
    Marques, Diogo F. P.
    Martinez-Baz, Ivan
    Mazagatos, Clara
    McMenamin, Jim
    Meijer, Adam
    Murray, Josephine L. K.
    Nunes, Baltazar
    O'Donnell, Joan
    Reynolds, Arlene
    Thorrington, Dominic
    Pebody, Richard
    Baguelin, Marc
    VACCINE, 2022, 40 (09) : 1306 - 1315
  • [14] Motivators for the public to receive the seasonal influenza vaccination and the effect of coronavirus disease 2019 pandemic on the uptake of the seasonal influenza vaccination
    Alamer, Naheel A.
    Al-Shammari, Malak A.
    Al-Johani, Wejdan M.
    Al-Mansour, Abdulelah H.
    Alshamlan, Nouf A.
    Alqarni, Amani M.
    Aldhawyan, Adam F.
    Alkaltham, Shikha M.
    Al-Muhaidib, Hala R.
    Darwish, Magdy A.
    JOURNAL OF FAMILY AND COMMUNITY MEDICINE, 2024, 31 (01) : 9 - 15
  • [15] Adherence of nurses to annual seasonal influenza vaccination over a 5-year period
    Chan, C. P.
    Lee, S. S.
    Wong, N. S.
    JOURNAL OF HOSPITAL INFECTION, 2021, 112 : 6 - 15
  • [16] The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly
    Blank, Patricia R.
    Schwenkglenks, Matthias
    Szucs, Thomas D.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (03) : 318 - 325
  • [17] Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling
    Dawa, Jeanette
    Emukule, Gideon O.
    Barasa, Edwine
    Widdowson, Marc Alain
    Anzala, Omu
    van Leeuwen, Edwin
    Baguelin, Marc
    Chaves, Sandra S.
    Eggo, Rosalind M.
    BMC MEDICINE, 2020, 18 (01)
  • [18] Does health plan type influence receipt of an annual influenza vaccination?
    Watson, Ian W.
    Oancea, Sanda Cristina
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2020, 74 (01) : 57 - 63
  • [19] Annual economic impacts of seasonal influenza on US counties: Spatial heterogeneity and patterns
    Mao, Liang
    Yang, Yang
    Qiu, Youliang
    Yang, Yan
    INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS, 2012, 11
  • [20] Establishing the health and economic impact of influenza vaccination within the European Union 25 countries
    Ryan, James
    Zoellner, York
    Gradl, Birgit
    Palache, Bram
    Medema, Jeroen
    VACCINE, 2006, 24 (47-48) : 6812 - 6822